Will Genentech Embrace PGx in Appeal of FDA Decision to Revoke Approval of Avastin in Breast Cancer?

In recommending the removal of the breast cancer indication from Avastin's label, the FDA urged Genentech "to conduct additional research to identify if there may be select groups of patients who might benefit from this drug."

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.